Biliary Drainage in Patients With Failed ERCP: Percutaneous Versus EUS-guided Drainage
Autor: | Félix I. Téllez-Ávila, David Herrera-Mora, Iván Casanova, Dayana Lindoro-Barraza, Gilberto Duarte-Medrano, Francisco Valdovinos-Andraca, Gustavo López-Arce, Javier Elizondo-Rivera, Miguel Ángel Ramírez-Luna |
---|---|
Rok vydání: | 2018 |
Předmět: |
Adult
Male medicine.medical_specialty Percutaneous Catheterization Endosonography Young Adult 03 medical and health sciences Postoperative Complications 0302 clinical medicine Bile Ducts Extrahepatic medicine Humans In patient Prospective Studies Treatment Failure Prospective cohort study Ultrasonography Interventional Aged Retrospective Studies Aged 80 and over Cholangiopancreatography Endoscopic Retrograde Biliary drainage Cholestasis Bile duct business.industry Retrospective cohort study Length of Stay Middle Aged Surgery Treatment Outcome medicine.anatomical_structure Bile Duct Neoplasms Needles Choledochostomy 030220 oncology & carcinogenesis Drainage Female Stents 030211 gastroenterology & hepatology Percutaneous transhepatic biliary drainage business Eus guided drainage |
Zdroj: | Surgical Laparoscopy, Endoscopy & Percutaneous Techniques. 28:183-187 |
ISSN: | 1530-4515 |
DOI: | 10.1097/sle.0000000000000528 |
Popis: | The goal of the study is to compare the efficacy and safety of bile duct drains guided by endoscopic ultrasound-guided biliary drainage (EGBD) versus percutaneous transhepatic biliary drainage (PTBD).Retrospective comparative study. Patients with obstruction of the bile duct who underwent the EGBD or PTBD procedure and had at least 1 previous endoscopic retrograde cholangiopancreatography that failed or was inaccessible to the second duodenal portion were included.A total of 90 patients were initially evaluated and 28 were excluded. There were 39 (62.9%) women, with a median age of 55.6 years (range, 22 to 88 y). The etiology of biliary obstruction was malignancy in 35 (56.4%) patients. Differences between EGBD versus PTBD groups were in technical success (90% vs. 78%; P=0.3), clinical success (96% vs. 63%; P=0.04), complications (6.6% vs. 28%; P=0.04), length of stay [6.5 d (range, 0 to 11 d) vs. 12.5 d (range, 6.2 to 25 d)] (P=0.009), and costs 1440.15±240.94 versus 2165.87±241.10 USD (P=0.03).EGBD is associated with a higher clinical success rate and safety, shorter hospital stays, and lower cost compared with PTBD. |
Databáze: | OpenAIRE |
Externí odkaz: |